26 completed, 6 terminated, 4 withdrawn, 2 active not recruiting. 21 Phase 1, 17 Phase 2, 2 Not applicable, 1 Early Phase 1.
Follow sonidegib: new trials by email Literature Review of sonidegib trials Research Report on sonidegib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular Carcinoma Irinotecan, Sonidegib, Sorafenib - Hepatocellular Carcinoma | Phase 2 | Recruiting | University of Florida | 12 | 2024-12-02 | 2026-07-14 |
| Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma Sonidegib, Cisplatin, Lomustine - Medulloblastoma | Phase 2 | Terminated | European Organisation for Research and Treatment of Cancer - EORTC | 20 | 2022-11-11 | 2025-10-23 |
| Oral Hedgehog Inhibitors in the Treatment of Basal Cell Carcinoma in the Netherlands: a Prospective Registration Study Vismodegib, Sonidegib - Basal Cell Carcinoma, Locally Advanced Basal Cell Carcinoma | Recruiting | Maastricht University Medical Center | 80 | 2021-11-01 | 2025-04-04 | |
| Anti-PD1-antibody and Pulsed HHI for Advanced BCC Cemiplimab Injection [Libtayo] - Basal Cell Carcinoma | Phase 2 | Unknown | Reinhard Dummer | 20 | 2021-02-18 | 2024-07-30 |
| Tailored Sonidegib Schedule After Complete Response in BCC Sonidegib - Locally Advanced Basal Cell Carcinoma | Phase 2 | Active not recruiting | Gruppo Oncologico del Nord-Ovest | 21 | 2021-01-12 | 2026-06-01 |
| Dose-Modulated Sonidegib Therapy for Periocular Basal Cell Carcinoma Sonidegib - Basal Cell Cancer, Eyelid Tumor | Completed | Federico II University | 12 | 2021-01-11 | 2025-07-16 | |
| Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors Pembrolizumab, Sonidegib - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8 | Phase 1 | Active not recruiting | Mayo Clinic | 36 | 2020-02-13 | 2026-03-18 |
| A Study to Evaluate Neoadjuvant Sonidegib Followed by Surgery or Imiquimod in the Management of Basal Cell Carcinoma Sonidegib, Imiquimod, Surgery - Basal Cell Carcinoma, Basal Cell Carcinoma of Skin, Site Unspecified | Phase 2 | Completed | Melanoma Institute Australia | 16 | 2019-07-23 | 2025-12-16 |
| Post-authorization Safety Study on the Long Term Safety of Sonidegib in Patients With Locally Advanced Cell Carcinoma sonidegib - Basal Cell Carcinoma | Completed | Sun Pharmaceutical Industries Limited | 323 | 2019-03-11 | 2026-03-18 | |
| SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors Gemcitabine, ribociclib, sonidegib - Anaplastic Astrocytoma, Anaplastic Ependymoma | Phase 1 | Completed | St. Jude Children's Research Hospital | 68 | 2018-03-05 | 2024-05-31 |
| Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma Buparlisib, Sonidegib - Carcinoma, Basal Cell, Recurrent Skin Cancer | Phase 2 | Terminated | Anne Chang | 10 | 2015-02-01 | 2019-01-29 |
| Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma LDE225, Bortezomib - Multiple Myeloma | Phase 2 | Terminated | SCRI Development Innovations, LLC | 7 | 2015-01-01 | 2017-02-16 |
| Phase IB Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer LDE225 - Recurrent Ovarian Cancer | Phase 1 | Completed | University of Alabama at Birmingham | 15 | 2014-09-01 | 2026-02-09 |
| LDE225 + Docetaxel/Prednisone for Adv/Met Castrate Resistant Prostate Cancer w/ Disease Progression After Docetaxel Docetaxel, Prednisone, LDE225 - Prostate Cancer | Phase 1 | Withdrawn | Martin Gutierrez | 2014-07-01 | 2019-06-19 | |
| LDE225 in Patients With Advanced or Metastatic Hepatocellular Carcinoma and Child-Pugh A/B7 Cirrhosis LDE225 - Hepatocellular Carcinoma, Cirrhosis | Phase 1 | Completed | Jason K. Sicklick, M.D. | 9 | 2014-07-01 | 2019-03-05 |
| Study of LDE225 (Sonidegib) in Combination With Docetaxel in Triple Negative (TN) Advanced Breast Cancer (ABC) Patients LDE225, Docetaxel - Advanced Breast Cancer | Phase 1 | Completed | Spanish Breast Cancer Research Group | 12 | 2014-05-01 | 2023-04-03 |
| Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies Azacitidine, Decitabine, Laboratory Biomarker Analysis - Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome | Phase 1 | Completed | Mayo Clinic | 63 | 2014-05-01 | 2019-10-30 |
| LDE225 in Treating Patients With Stage II-III Estrogen Receptor- and HER2-Negative Breast Cancer Erismodegib, Placebo - Breast Neoplasms | Phase 2 | Withdrawn | Washington University School of Medicine | 2014-04-01 | 2015-04-27 | |
| Phase I Trial of LDE225 for Steroid-refractory Chronic GVHD After Allogeneic HSCT LDE225 - Graft Versus Host Disease | Phase 1 | Terminated | Massachusetts General Hospital | 17 | 2014-04-01 | 2018-03-19 |
| A Pre-surgical Study of LDE225 in Men With High-risk Localized Prostate Cancer LDE225 - Prostate Cancer | Phase 1 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 14 | 2014-04-01 | 2019-03-07 |
Showing 20 of 41. Sign in to see all of them.
Carcinoma, Basal Cell (11) · Medulloblastoma (6) · Basal Cell Nevus Syndrome (4) · Recurrence (4) · Skin Neoplasms (4) · Astrocytoma (2) · Breast Neoplasms (2) · Carcinoma (2) · Carcinoma, Hepatocellular (2) · Glioblastoma (2) · Glioma (2) · Leukemia, Myeloid, Acute (2) · Lung Neoplasms (2) · Multiple Myeloma (2) · Neoplasm Metastasis (2)
Novartis Pharmaceuticals (13) · Mayo Clinic (3) · Anne Chang (2) · Massachusetts General Hospital (2) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Federico II University (1) · Gruppo Oncologico del Nord-Ovest (1) · Jason K. Sicklick, M.D. (1) · Maastricht University Medical Center (1) · Martin Gutierrez (1) · Melanoma Institute Australia (1) · Memorial Sloan Kettering Cancer Center (1) · Reinhard Dummer (1) · Rutgers, The State University of New Jersey (1)
United States (27) · Germany (10) · Italy (10) · Spain (10) · Australia (8) · Canada (8) · Switzerland (7) · United Kingdom (7) · Belgium (6) · France (6) · Netherlands (5) · Austria (3) · Hungary (2) · Brazil (1) · Bulgaria (1)
Ali Zarrinpar, MD, PhD (1) · Ana De Jesus-Acosta, MD (1) · Anastasios Stathis, MD (1) · Anne Chang, MD (1) · Anne Lynn Chang, MD (1) · Aref Al-Kali (1) · Charles A Leath, III, MD, MSPH (1) · Charles Rudin, MD (1) · Cristiana Sessa, Prof Dr med (1) · Cynthia Ma, M.D., Ph.D. (1) · Darren Carpizo, MD, PhD (1) · Diego Strianese, MD, PhD (1) · Emmanuel Antonarakis, M.D. (1) · Francis Buadi (1)
PMID 25981810, PMID 26546616, PMID 27467121, PMID 28846163, PMID 29175429, PMID 29296838, PMID 29948356, PMID 30042390, PMID 32634234, PMID 32736411, PMID 34669179, PMID 34798846, PMID 39538176
P30CA015083 (2), 2008 (1), P30CA072720 (1)